8892 results
Cited 15 times since 2014 (1.4 per year)
source: EuropePMC
European journal of epidemiology,
Volume 29, Issue 11, 12 2 2014, Pages 841-850
Comparing a marginal structural model with a Cox proportional hazard model to estimate the effect of time-dependent drug use in observational studies: statin use for primary prevention of cardiovascular disease as an example from the Rotterdam Study.
de Keyser CE, Leening MJ, Romio SA, Jukema JW, Hofman A, Ikram MA, Franco OH, Stijnen T, Stricker BH
When studying the causal effect of drug use in observational data, marginal structural modeling (MSM) can be used to adjust for time-dependent confounders that are affected by previous treatment. The objective of this study was to compare traditional Cox proportional hazard models (with and without time-dependent covariates) with MSM to study causal effects of time-dependent drug use. The example of primary prevention of cardiovascular disease (CVD) with statins was examined using up to 17.7 yea...
Abstract
Cited 11 times since 2014 (1 per year)
source: EuropePMC
Preventive veterinary medicine,
Volume 116, Issue 4, 10 2 2014, Pages 341-349
Response to an emerging vector-borne disease: surveillance and preparedness for Schmallenberg virus.
Roberts HC, Elbers AR, Conraths FJ, Holsteg M, Hoereth-Boentgen D, Gethmann J, van Schaik G
Surveillance for new emerging animal diseases from a European perspective is complicated by the non-harmonised approach across Member States for data capture, recording livestock populations and case definitions. In the summer of 2011, a new vector-borne Orthobunyavirus emerged in Northern Europe and for the first time, a coordinated approach to horizon scanning, risk communication, data and diagnostic test sharing allowed EU Member States to develop early predictions of the disease, its impact...
Abstract
Cited 11 times since 2014 (1 per year)
source: EuropePMC
European heart journal. Acute cardiovascular care,
Volume 4, Issue 3, 10 2 2014, Pages 254-262
Contemporary inter-hospital transfer patterns for the management of acute coronary syndrome patients: findings from the EPICOR study.
Sinnaeve PR, Zeymer U, Bueno H, Danchin N, Medina J, Sánchez-Covisa J, Licour M, Annemans L, Jukema JW, Pocock S, Storey RF, Van de Werf F
Aim: The EPICOR observational study was designed to describe antithrombotic strategies in a broad acute coronary syndrome (ACS) population; it also included information on inter-hospital transfers and institutional resources. Methods and results: EPICOR enrolled 10,568 consecutively discharged patients with ST-elevation (STE) or non-STE (NSTE) ACS in 555 centres in 20 countries across Europe and Latin America. Patients were categorized as non-transferred, transferred in from another hospital and...
Abstract
Cited 19 times since 2014 (1.7 per year)
source: EuropePMC
Public health genomics,
Volume 17, Issue 5-6, 9 2 2014, Pages 280-286
Stakeholder analysis in pharmacogenomics and genomic medicine in Greece.
Mitropoulou C, Mai Y, van Schaik RH, Vozikis A, Patrinos GP
Background: The pace of discoveries and advances in genomic research is not reflected in the pace of their translation and incorporation into day-to-day clinical medicine to individualize healthcare decision-making processes. One of the main obstacles is the poor understanding of the policies and the key stakeholders involved in these translation processes. Methods: We used the computerized version of the PolicyMaker political mapping tool to collect and organize important information about the...
Abstract
Cited 34 times since 2014 (3.1 per year)
source: EuropePMC
Preventive veterinary medicine,
Volume 117, Issue 1, 8 2 2014, Pages 103-109
Prevalence and risk factors for Coxiella burnetii (Q fever) in Dutch dairy cattle herds based on bulk tank milk testing.
van Engelen E, Schotten N, Schimmer B, Hautvast JL, van Schaik G, van Duijnhoven YT
Despite cattle herds can harbor Coxiella burnetii, risk factors for C. burnetii presence in dairy cattle herds are largely unknown. Therefore, C. burnetii herd prevalence and risk factors for bulk tank milk (BTM) positivity were investigated. In this cross-sectional study, a questionnaire was filled out by the farmer and BTM from 301 farms was tested by ELISA for presence of C. burnetii antibodies and PCR for presence of C. burnetii DNA. Risk factors were identified by univariable and multivaria...
Abstract
Cited 21 times since 2014 (1.9 per year)
source: EuropePMC
Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation,
Volume 22, Issue 9, 1 1 2014, Pages 363-369
Normal and abnormal development of the aortic wall and valve: correlation with clinical entities.
Grewal N, DeRuiter MC, Jongbloed MR, Goumans MJ, Klautz RJ, Poelmann RE, Gittenberger-de Groot AC
Dilation of the wall of the thoracic aorta can be found in patients with a tricuspid (TAV) as well as a bicuspid aortic valve (BAV) with and without a syndromic component. BAV is the most common congenital cardiovascular malformation, with a population prevalence of 0.5-2 %. The clinical course is often characterised by aneurysm formation and in some cases dissection. The non-dilated aortic wall is less well differentiated in all BAV as compared with TAV, thereby conferring inherent developmenta...
Abstract
Cited 71 times since 2014 (6.4 per year)
source: EuropePMC
European heart journal,
Volume 36, Issue 3, 1 1 2014, Pages 158-169
EuroEco (European Health Economic Trial on Home Monitoring in ICD Patients): a provider perspective in five European countries on costs and net financial impact of follow-up with or without remote monitoring.
Heidbuchel H, Hindricks G, Broadhurst P, Van Erven L, Fernandez-Lozano I, Rivero-Ayerza M, Malinowski K, Marek A, Romero Garrido RF, Löscher S, Beeton I, Garcia E, Cross S, Vijgen J, Koivisto UM, Peinado R, Smala A, Annemans L
Aim: Remote follow-up (FU) of implantable cardiac defibrillators (ICDs) allows for fewer in-office visits in combination with earlier detection of relevant findings. Its implementation requires investment and reorganization of care. Providers (physicians or hospitals) are unsure about the financial impact. The primary end-point of this randomized prospective multicentre health economic trial was the total FU-related cost for providers, comparing Home Monitoring facilitated FU (HM ON) to regular...
Abstract
Cited 47 times since 2014 (4.2 per year)
source: EuropePMC
Molecular therapy : the journal of the American Society of Gene Therapy,
Volume 22, Issue 11, 1 1 2014, Pages 1960-1970
Neovascularization capacity of mesenchymal stromal cells from critical limb ischemia patients is equivalent to healthy controls.
Gremmels H, Teraa M, Quax PH, den Ouden K, Fledderus JO, Verhaar MC
Critical limb ischemia (CLI) is often poorly treatable by conventional management and alternatives such as autologous cell therapy are increasingly investigated. Whereas previous studies showed a substantial impairment of neovascularization capacity in primary bone-marrow (BM) isolates from patients, little is known about dysfunction in patient-derived BM mesenchymal stromal cells (MSCs). In this study, we have compared CLI-MSCs to healthy controls using gene expression profiling and functional...
Abstract
Cited 8 times since 2014 (0.7 per year)
source: EuropePMC
Pharmacogenetics and genomics,
Volume 24, Issue 9, 1 1 2014, Pages 427-435
Genetic variance in ABCB1 and CYP3A5 does not contribute toward the development of chronic kidney disease after liver transplantation.
Tapirdamaz Ö, Hesselink DA, el Bouazzaoui S, Azimpour M, Hansen B, van der Laan LJ, Polak WG, Kwekkeboom J, van Schaik RH, van Gelder T, Metselaar HJ
Introduction: Chronic kidney disease (CKD) after liver transplantation (LT) is a major clinical problem that appears to be associated with nongenetic as well as genetic determinants. Calcineurin inhibitor (CNI) use is considered to play a major role in the development of CKD after LT. We studied the influence of single-nucleotide polymorphisms (SNPs) in the genes of the donor and recipient CNI-metabolizing enzyme CYP3A5 and the CNI-transporting ABCB1 on the development of CKD after LT. Materials...
Abstract
Cited 11 times since 2014 (1 per year)
source: EuropePMC
AIDS (London, England),
Volume 28, Issue 15, 1 1 2014, Pages 2259-2268
Pregnancy outcomes and birth defects from an antiretroviral drug safety study of women in South Africa and Zambia.
Liu KC, Farahani M, Mashamba T, Mawela M, Joseph J, Van Schaik N, Honey E, Gill M, Jassat W, Stringer EM, Chintu N, Marlink RG
Objective: To evaluate the safety of combination antiretroviral therapy (ART) in conception and pregnancy in different health systems. Design: A pilot ART registry to measure the prevalence of birth defects and adverse pregnancy outcomes in South Africa and Zambia. Methods: HIV-infected pregnant women on ART prior to conception were enrolled until delivery, and their infants were followed until 1 year old. Results: Between October 2010 and April 2011, 600 women were enrolled. The median CD4 cell...
Abstract
Cited 1180 times since 2014 (105.9 per year)
source: EuropePMC
Science (New York, N.Y.),
Volume 345, Issue 6204, 1 1 2014, Pages 1251086
Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity.
Saeed S, Quintin J, Kerstens HH, Rao NA, Aghajanirefah A, Matarese F, Cheng SC, Ratter J, Berentsen K, van der Ent MA, Sharifi N, Janssen-Megens EM, Ter Huurne M, Mandoli A, van Schaik T, Ng A, Burden F, Downes K, Frontini M, Kumar V, Giamarellos-Bourboulis EJ, Ouwehand WH, van der Meer JW, Joosten LA, Wijmenga C, Martens JH, Xavier RJ, Logie C, Netea MG, Stunnenberg HG
Monocyte differentiation into macrophages represents a cornerstone process for host defense. Concomitantly, immunological imprinting of either tolerance or trained immunity determines the functional fate of macrophages and susceptibility to secondary infections. We characterized the transcriptomes and epigenomes in four primary cell types: monocytes and in vitro-differentiated naïve, tolerized, and trained macrophages. Inflammatory and metabolic pathways were modulated in macrophages, including...
Abstract
The International journal of angiology : official publication of the International College of Angiology, Inc,
Volume 23, Issue 3, 1 1 2014, Pages 207-214
Impact of Timing of Eptifibatide Administration on Preprocedural Infarct-Related Artery Patency in Acute STEMI Patients Undergoing Primary PCI.
Dharma S, Firdaus I, Danny SS, Juzar DA, Wardeh AJ, Jukema JW, van der Laarse A
The appropriate timing of eptifibatide initiation for acute ST segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI) remains unclear. This study aimed to analyze the impact of timing of eptifibatide administration on infarct-related artery (IRA) patency in STEMI patients undergoing primary PCI. Acute STEMI patients who underwent primary PCI (n = 324) were enrolled in this retrospective study; 164 patients received eptifibatide bolus ...
Abstract
Cited 7 times since 2014 (0.6 per year)
source: EuropePMC
International journal of radiation oncology, biology, physics,
Volume 90, Issue 1, 1 1 2014, Pages 164-171
Impact of cardiovascular counseling and screening in Hodgkin lymphoma survivors.
Daniëls LA, Krol SD, de Graaf MA, Scholte AJ, van 't Veer MB, Putter H, de Roos A, Schalij MJ, van de Poll-Franse LV, Creutzberg CL
Purpose: Cardiovascular disease (CVD) is the most common nonmalignant cause of death in Hodgkin lymphoma (HL) survivors, especially after mediastinal irradiation. The role of screening for CVD in HL survivors is unclear, but confrontation with risks of CVD may have a negative influence on health-related quality of life (HRQL). As part of a phase 2 screening study using computed tomography angiography (CTA) among HL survivors, an HRQL analysis was done to evaluate the emotional and practical burd...
Abstract
Cited 283 times since 2014 (25.4 per year)
source: EuropePMC
The New England journal of medicine,
Volume 371, Issue 12, 31 5 2014, Pages 1091-1099
Ivabradine in stable coronary artery disease without clinical heart failure.
Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R, SIGNIFY Investigators
Background: An elevated heart rate is an established marker of cardiovascular risk. Previous analyses have suggested that ivabradine, a heart-rate-reducing agent, may improve outcomes in patients with stable coronary artery disease, left ventricular dysfunction, and a heart rate of 70 beats per minute or more. Methods: We conducted a randomized, double-blind, placebo-controlled trial of ivabradine, added to standard background therapy, in 19,102 patients who had both stable coronary artery disea...
Abstract
Cited 3023 times since 2014 (271.2 per year)
source: EuropePMC
European heart journal,
Volume 35, Issue 37, 29 5 2014, Pages 2541-2619
2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).
Authors/Task Force members, Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A
Abstract
Cited 2706 times since 2014 (242.7 per year)
source: EuropePMC
European heart journal,
Volume 35, Issue 41, 29 5 2014, Pages 2873-2926
2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC).
Erbel R, Aboyans V, Boileau C, Bossone E, Bartolomeo RD, Eggebrecht H, Evangelista A, Falk V, Frank H, Gaemperli O, Grabenwöger M, Haverich A, Iung B, Manolis AJ, Meijboom F, Nienaber CA, Roffi M, Rousseau H, Sechtem U, Sirnes PA, Allmen RS, Vrints CJ, ESC Committee for Practice Guidelines
Abstract
Cited 1533 times since 2014 (137.5 per year)
source: EuropePMC
European heart journal,
Volume 35, Issue 43, 29 5 2014, Pages 3033-69, 3069a-3069k
2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism.
Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galiè N, Gibbs JS, Huisman MV, Humbert M, Kucher N, Lang I, Lankeit M, Lekakis J, Maack C, Mayer E, Meneveau N, Perrier A, Pruszczyk P, Rasmussen LH, Schindler TH, Svitil P, Vonk Noordegraaf A, Zamorano JL, Zompatori M, Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC)
Abstract
Cited 531 times since 2014 (47.6 per year)
source: EuropePMC
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery,
Volume 46, Issue 4, 29 5 2014, Pages 517-592
2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).
Kolh P, Windecker S, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A, European Society of Cardiology Committee for Practice Guidelines, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol Ç, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, EACTS Clinical Guidelines Committee, Sousa Uva M, Achenbach S, Pepper J, Anyanwu A, Badimon L, Bauersachs J, Baumbach A, Beygui F, Bonaros N, De Carlo M, Deaton C, Dobrev D, Dunning J, Eeckhout E, Gielen S, Hasdai D, Kirchhof P, Luckraz H, Mahrholdt H, Montalescot G, Paparella D, Rastan AJ, Sanmartin M, Sergeant P, Silber S, Tamargo J, ten Berg J, Thiele H, van Geuns RJ, Wagner
Abstract
Cited 2742 times since 2014 (246 per year)
source: EuropePMC
European heart journal,
Volume 35, Issue 39, 29 5 2014, Pages 2733-2779
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).
Authors/Task Force members, Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont A, Limongelli G, Mahrholdt H, McKenna WJ, Mogensen J, Nihoyannopoulos P, Nistri S, Pieper PG, Pieske B, Rapezzi C, Rutten FH, Tillmanns C, Watkins H
Abstract
Cited 23 times since 2014 (2.1 per year)
source: EuropePMC
The international journal of cardiovascular imaging,
Volume 31, Issue 1, 27 4 2014, Pages 151-161
Automatic detection and quantification of the Agatston coronary artery calcium score on contrast computed tomography angiography.
Ahmed W, de Graaf MA, Broersen A, Kitslaar PH, Oost E, Dijkstra J, Bax JJ, Reiber JH, Scholte AJ
Potentially, Agatston coronary artery calcium (CAC) score could be calculated on contrast computed tomography coronary angiography (CTA). This will make a separate non-contrast CT scan superfluous. This study aims to assess the performance of a novel fully automatic algorithm to detect and quantify the Agatston CAC score in contrast CTA images. From a clinical registry, 20 patients were randomly selected for each CAC category (i.e. 0, 1-99, 100-399, 400-999, ≥1,000). The Agatston CAC score on no...
Abstract
